New antibody-drug combo targets tough cervical cancers in early trial
NCT ID NCT05838521
First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 2 times
Summary
This study tests a drug called sacituzumab govitecan in 20 people whose cervical cancer has returned or persisted after at least one prior chemotherapy. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The main goal is to see how many patients' tumors shrink or disappear, and researchers will also track survival and side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cleveland Clinic
RECRUITINGCleveland, Ohio, 44195, United States
-
Smilow Cancer Hospital at Yale New Haven
RECRUITINGNew Haven, Connecticut, 06520, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can an antiviral make radiation more effective against cervical cancer?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Can a Two-Antibody combo outsmart advanced cancer?
- Can robotic surgery match open surgery in beating cervical cancer?
- Blood test clues could sharpen cervical cancer treatment